Ocular Therapeutix (NSDQ:OCUL) said today that the FDA has approved a supplemental NDA for its dexamethasone ocular insert, Dextenza.
The Bedford, Mass.-based company requested in January that the U.S. regulatory agency expand the current indication for Dextenza to include the treatment of ocular inflammation following eye surgery.
Dextenza is designed to deliver drugs for up to 30 days following treatment in a physician’s office. The company’s drug-delivery device was approved in November for the treatment of pain following eye surgery.
Get the full story on our sister site, Drug Delivery Business.